P079 HOME BLOOD PRESSURE SCREENING IN MAY MEASUREMENT MONTH 2022 USING THE ZOE HEALTH STUDY APP

Background and Objective: May Measurement Month (MMM) is a global blood pressure (BP) screening campaign with aims to raise awareness of raised BP. In 2022, MMM incorporated home BP measurements from UK users of the ZOE Health Study app. We compare rates of hypertension prevalence, treatment, and control amongst ZOE app users with other European non-ZOE MMM participants. Methods: Adult (≥18 years) UK ZOE app users were invited to participate in MMM in 2022. ZOE participants were advised on taking three home BP measurements and non-ZOE participants had three standardised seated BP measurements in a range of facilities outside the home. All participants completed a questionnaire including demographics and antihypertensive medication use. Hypertension was defined using thresholds for clinic BP (≥140/90 mmHg) for non-ZOE participants and thresholds for home BP (≥135/85 mmHg) for ZOE participants, based on the mean of the second and third measurements, and/or taking antihypertensive medication. Awareness was defined as having a previous diagnosis of hypertension or treatment with antihypertensive medication. Results: A total of 50,200 ZOE participants were screened in MMM22, of whom 94.0% were over 50 years of age and 65.8% were female. 24,967 (49.7%) were hypertensive, of whom 19,356 (77.5%) were aware, and 18,195 (72.9%) were taking antihypertensive medication, and 11,454 (45.9%) were controlled to <135/85 mmHg. Compared to the other 64,256 MMM22 European participants (mean age 53.6 [SD 16.8] years, 58.7% female), ZOE participants had slightly higher rates of hypertension (49.7% vs 48.9%), and greater proportions of ZOE hypertensive participants were aware (77.5% vs 70.8%), treated (72.9% vs 63.3%), and controlled to <135/85 in ZOE participants and <140/90 mmHg in non-ZOE participants (45.9% vs 30.9%) (p<0.001 for all). Conclusions: In this large UK sample of ZOE users with hypertension, a higher proportion were aware, treated and controlled than amongst other European MMM screenees with hypertension. These digitally-enabled ZOE users apparently have greater access or engagement with effective BP management strategies.